TY - JOUR
T1 - Aspirin and the Primary Prevention of Cardiovascular Diseases
T2 - An Approach Based on Individualized, Integrated Estimation of Risk
AU - Volpe, Massimo
AU - Battistoni, Allegra
AU - Gallo, Giovanna
AU - Coluccia, Roberta
AU - De Caterina, Raffaele
PY - 2017/9/1
Y1 - 2017/9/1
N2 - While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings. Recently, emerging evidence suggests the possibility that the assumption of aspirin, may also be effective in the prevention of cancer. By adding to the CV prevention benefits the potential beneficial effect of aspirin in reducing the incidence of mortality and cancer could tip the balance between risks and benefits of aspirin therapy in the primary prevention in favour of the latter and broaden the indication for treatment with in populations at average risk. While prospective and randomized study are currently investigating the effect of aspirin in prevention of both cancer and CVD, clinical efforts at the individual level to promote the use of aspirin in global (or total) primary prevention could be already based on a balanced evaluation of the benefit/risk ratio.
AB - While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings. Recently, emerging evidence suggests the possibility that the assumption of aspirin, may also be effective in the prevention of cancer. By adding to the CV prevention benefits the potential beneficial effect of aspirin in reducing the incidence of mortality and cancer could tip the balance between risks and benefits of aspirin therapy in the primary prevention in favour of the latter and broaden the indication for treatment with in populations at average risk. While prospective and randomized study are currently investigating the effect of aspirin in prevention of both cancer and CVD, clinical efforts at the individual level to promote the use of aspirin in global (or total) primary prevention could be already based on a balanced evaluation of the benefit/risk ratio.
KW - Aspirin
KW - Cancer
KW - Cardiovascular risk
KW - Primary prevention
UR - http://www.scopus.com/inward/record.url?scp=85028543884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028543884&partnerID=8YFLogxK
U2 - 10.1007/s40292-017-0213-4
DO - 10.1007/s40292-017-0213-4
M3 - Article
C2 - 28573479
AN - SCOPUS:85028543884
VL - 24
SP - 331
EP - 339
JO - High Blood Pressure and Cardiovascular Prevention
JF - High Blood Pressure and Cardiovascular Prevention
SN - 1120-9879
IS - 3
ER -